Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 7c; Offers FY23 Revenue Guidance
May 4, 2023 8:21 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $38.7 million versus the consensus estimate of $36.3 million.
GUIDANCE:
Karyopharm Therapeutics sees FY2023 revenue of $145-160 million, versus the consensus of... More
